New ICD-10-PCS Codes in

734 codes were added to the 2020 ICD-10-PCS code set, effective October 1, 2019.

Displaying codes 701-734 of 734:

  • X27R3C5 Dilation of Right Posterior Tibial Artery with Four or More Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27S385 Dilation of Left Posterior Tibial Artery with Sustained Release Drug-eluting Intraluminal Device, Percutaneous Approach, New Technology Group 5
  • X27S395 Dilation of Left Posterior Tibial Artery with Two Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27S3B5 Dilation of Left Posterior Tibial Artery with Three Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27S3C5 Dilation of Left Posterior Tibial Artery with Four or More Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27T385 Dilation of Right Peroneal Artery with Sustained Release Drug-eluting Intraluminal Device, Percutaneous Approach, New Technology Group 5
  • X27T395 Dilation of Right Peroneal Artery with Two Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27T3B5 Dilation of Right Peroneal Artery with Three Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27T3C5 Dilation of Right Peroneal Artery with Four or More Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27U385 Dilation of Left Peroneal Artery with Sustained Release Drug-eluting Intraluminal Device, Percutaneous Approach, New Technology Group 5
  • X27U395 Dilation of Left Peroneal Artery with Two Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27U3B5 Dilation of Left Peroneal Artery with Three Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X27U3C5 Dilation of Left Peroneal Artery with Four or More Sustained Release Drug-eluting Intraluminal Devices, Percutaneous Approach, New Technology Group 5
  • X2A6325 Cerebral Embolic Filtration, Single Deflection Filter in Aortic Arch, Percutaneous Approach, New Technology Group 5
  • XT25XE5 Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5
  • XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW033K5 Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033N5 Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033S5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033U5 Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033W5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW043K5 Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043N5 Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043U5 Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW0DXJ5 Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0DXL5 Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0DXR5 Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0DXT5 Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0DXV5 Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
  • XXE5XM5 Measurement of Infection, Whole Blood Nucleic Acid-base Microbial Detection, New Technology Group 5